163 related articles for article (PubMed ID: 35444161)
1. Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.
Fujita M; Abe K; Kuroda H; Oikawa T; Ninomiya M; Masamune A; Okumoto K; Katsumi T; Sato W; Iijima K; Endo T; Fukuda S; Tanabe N; Numao H; Takikawa Y; Ueno Y; Ohira H
Sci Rep; 2022 Apr; 12(1):6479. PubMed ID: 35444161
[TBL] [Abstract][Full Text] [Related]
2. Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis.
Fujita M; Abe K; Hayashi M; Takahashi A; Ohira H
Medicine (Baltimore); 2020 Jul; 99(28):e21061. PubMed ID: 32664122
[TBL] [Abstract][Full Text] [Related]
3. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma.
Fujita M; Takahashi A; Hayashi M; Okai K; Abe K; Ohira H
Hepatol Res; 2019 Jul; 49(7):778-786. PubMed ID: 30884044
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
[TBL] [Abstract][Full Text] [Related]
7. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
8. A lower psoas muscle volume was associated with a higher rate of recurrence in male clear cell renal cell carcinoma.
Noguchi G; Kawahara T; Kobayashi K; Tsutsumi S; Ohtake S; Osaka K; Umemoto S; Nakaigawa N; Uemura H; Kishida T; Yao M
PLoS One; 2020; 15(1):e0226581. PubMed ID: 31895931
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
10. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.
Zhang JX; Yan HT; Ding Y; Liu J; Liu S; Zu QQ; Shi HB
Ann Med; 2022 Dec; 54(1):1562-1569. PubMed ID: 35639492
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume.
Imai K; Takai K; Watanabe S; Hanai T; Suetsugu A; Shiraki M; Shimizu M
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28937616
[TBL] [Abstract][Full Text] [Related]
12. Impact of skeletal muscle mass on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Uchida Y; Ishii H; Tanaka A; Yonekawa J; Satake A; Makino Y; Suzuki W; Kurobe M; Mizutani K; Mizutani Y; Fujimoto M; Ichimiya H; Teramoto C; Tamenishi A; Okamoto H; Watanabe J; Kanashiro M; Amano T; Matsubara T; Ichimiya S; Murohara T
Cardiovasc Interv Ther; 2021 Oct; 36(4):514-522. PubMed ID: 33128695
[TBL] [Abstract][Full Text] [Related]
13. Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study.
Tateyama M; Naoe H; Tanaka M; Tanaka K; Narahara S; Tokunaga T; Kawasaki T; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Sasaki Y; Tanaka Y
BMC Gastroenterol; 2020 Nov; 20(1):371. PubMed ID: 33167879
[TBL] [Abstract][Full Text] [Related]
14. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis.
Ebadi M; Wang CW; Lai JC; Dasarathy S; Kappus MR; Dunn MA; Carey EJ; Montano-Loza AJ;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1053-1062. PubMed ID: 30269421
[TBL] [Abstract][Full Text] [Related]
15. CT anthropometric analysis of the prognosis of traumatic brain injury: A retrospective study to compare between psoas muscle and abdominal skeletal muscle.
Cho HJ; Hwang Y; Yang SY; Kim M
Injury; 2022 May; 53(5):1652-1657. PubMed ID: 35241285
[TBL] [Abstract][Full Text] [Related]
16. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
17. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
[TBL] [Abstract][Full Text] [Related]
18. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
19. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
Yamaoka K; Kodama K; Kawaoka T; Kosaka M; Johira Y; Shirane Y; Miura R; Yano S; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Uchikawa S; Uchida T; Fujino H; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Miki D; Imamura M; Takahashi S; Nagao A; Chayama K; Aikata H
PLoS One; 2022; 17(1):e0262675. PubMed ID: 35041693
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
